Genmab — December 2025
-
Genmab gør et godt helhedsindtryk med sine studiedata mener Jyske Bank https://proinvestor.com/investornyt/1390946/genmab-gor-et-godt-helhedsindtryk-med-sine-studiedata-mener-jyske-bank
-
RedirecTT-1 Talquetamab (GPRC5D) + Teclistamab (BCMA) - Dual Targeting of Extramedullary Myeloma with Talquetamab and Teclistamab - https://www.nejm.org/doi/full/10.1056/NEJMoa2514752 https://x.com/DrRishabhOnco/status/1997930035827929089
-
for those that didn't read genmab's press release, the FL data was also published in the Lancet - Epcoritamab, lenalidomide, and rituximab versus lenalidomide and rituximab for relapsed or refractory follicular lymphoma (EPCORE FL-1): a global, open-label, randomised, phase 3 trial https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(25)02360-8/fulltext
-
Genmab Announces New Data from Phase 1b/2 EPCORE
CLL-1 Highlighting Potential of Epcoritamab as Monotherapy and in Combination for Patients with Richter Transformation (RT) https://proinvestor.com/investornyt/1391260/genmab-announces-new-data-from-phase-1b-2-epcore-cll-1-highlighting-potential-of-epcoritamab-as-monotherapy-and-in-combination-for-patients-with-richter-transformation-rt -
Genmabs kræftmiddel viser opmuntrende resultater mod Richter transformation https://proinvestor.com/investornyt/1391335/genmabs-kraeftmiddel-viser-opmuntrende-resultater-mod-richter-transformation
-
-
#ASH25 | PRESENTATION
Philip Thompson,
@MDAndersonNews@PeterMacCC
, presents first results of epcoritamab + lenalidomide (Arm 2B; N = 11) and epcoritamab + R-CHOP (Arm 2C; N = 30) in patients with Richter transformation from the phase Ib/II EPCORE CLL-1 trial. https://x.com/lymphomahub/status/1998150848279609470 -
ASH: J&J makes case for Tecvayli combo as an alternative to CAR-T in 2nd-line multiple myeloma https://www.fiercepharma.com/pharma/jj-makes-case-tecvayli-combo-alternative-car-t-second-line-multiple-myeloma
-
Unprecedented results from the Phase 3 MajesTEC-3 study support TECVAYLI
plus DARZALEX FASPRO as a potential standard of care as early as second line for patients with relapsed/refractory multiple myeloma https://www.prnewswire.com/news-releases/unprecedented-results-from-the-phase-3-majestec-3-study-support-tecvayli-plus-darzalex-faspro-as-a-potential-standard-of-care-as-early-as-second-line-for-patients-with-relapsedrefractory-multiple-myeloma-302636559.html?tc=eml_cleartime
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind